An ongoing study has unveiled an encouraging prospect, delineating the efficacy of PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy as a novel and auspicious clinical trajectory for the treatment of triple-negative breast cancer [33]. In a recent study, the inclusion of PD-1 immune checkpoint inhibitor pembrolizumab alongside conventional neoadjuvant chemotherapy resulted in a doubling of the estimated pathological complete response compared to chemotherapy alone. Here, CD274 is linked to triple-negative breast carcinoma.